United Therapeutics (UTHR) Competitors $433.61 -6.45 (-1.47%) Closing price 10/14/2025 04:00 PM EasternExtended Trading$437.80 +4.19 (+0.97%) As of 08:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock UTHR vs. REGN, ALNY, BIIB, INCY, NBIX, IONS, EXEL, EXAS, BMRN, and MDGLShould you be buying United Therapeutics stock or one of its competitors? The main competitors of United Therapeutics include Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Incyte (INCY), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exelixis (EXEL), Exact Sciences (EXAS), BioMarin Pharmaceutical (BMRN), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "biotechnology" industry. United Therapeutics vs. Its Competitors Regeneron Pharmaceuticals Alnylam Pharmaceuticals Biogen Incyte Neurocrine Biosciences Ionis Pharmaceuticals Exelixis Exact Sciences BioMarin Pharmaceutical Madrigal Pharmaceuticals Regeneron Pharmaceuticals (NASDAQ:REGN) and United Therapeutics (NASDAQ:UTHR) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation. Does the media favor REGN or UTHR? In the previous week, Regeneron Pharmaceuticals had 36 more articles in the media than United Therapeutics. MarketBeat recorded 53 mentions for Regeneron Pharmaceuticals and 17 mentions for United Therapeutics. Regeneron Pharmaceuticals' average media sentiment score of 0.95 beat United Therapeutics' score of 0.86 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regeneron Pharmaceuticals 27 Very Positive mention(s) 8 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive United Therapeutics 8 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, REGN or UTHR? Regeneron Pharmaceuticals has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500. Comparatively, United Therapeutics has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500. Do analysts recommend REGN or UTHR? Regeneron Pharmaceuticals currently has a consensus target price of $817.88, indicating a potential upside of 42.84%. United Therapeutics has a consensus target price of $457.21, indicating a potential upside of 5.44%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than United Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regeneron Pharmaceuticals 1 Sell rating(s) 7 Hold rating(s) 18 Buy rating(s) 3 Strong Buy rating(s) 2.79United Therapeutics 0 Sell rating(s) 5 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.67 Do insiders and institutionals believe in REGN or UTHR? 83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 94.1% of United Therapeutics shares are owned by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are owned by company insiders. Comparatively, 10.3% of United Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has preferable earnings & valuation, REGN or UTHR? Regeneron Pharmaceuticals has higher revenue and earnings than United Therapeutics. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRegeneron Pharmaceuticals$14.21B4.27$4.41B$39.6814.43United Therapeutics$2.88B6.80$1.20B$25.6216.92 Is REGN or UTHR more profitable? United Therapeutics has a net margin of 40.36% compared to Regeneron Pharmaceuticals' net margin of 31.37%. United Therapeutics' return on equity of 18.73% beat Regeneron Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Regeneron Pharmaceuticals31.37% 15.06% 11.77% United Therapeutics 40.36%18.73%16.49% SummaryRegeneron Pharmaceuticals beats United Therapeutics on 9 of the 17 factors compared between the two stocks. Get United Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding UTHR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UTHR vs. The Competition Export to ExcelMetricUnited TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.85B$2.63B$6.04B$10.50BDividend YieldN/A57.77%5.73%4.80%P/E Ratio16.9222.5684.2027.24Price / Sales6.80550.25510.92196.48Price / Cash15.50174.0137.5761.53Price / Book3.005.3612.226.74Net Income$1.20B$33.06M$3.32B$276.59M7 Day Performance-3.41%-1.31%-1.32%-0.47%1 Month Performance7.57%11.42%8.15%7.47%1 Year Performance20.59%-1.34%71.76%34.58% United Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UTHRUnited Therapeutics4.3891 of 5 stars$433.61-1.5%$457.21+5.4%+21.4%$19.85B$2.88B16.921,305REGNRegeneron Pharmaceuticals4.7639 of 5 stars$585.48-2.4%$817.67+39.7%-43.5%$63.59B$14.20B15.4715,106Trending NewsAnalyst ForecastAnalyst RevisionALNYAlnylam Pharmaceuticals4.0012 of 5 stars$452.00-1.0%$448.04-0.9%+65.7%$59.82B$2.25B0.002,230Analyst DowngradeAnalyst RevisionBIIBBiogen4.6666 of 5 stars$154.05-3.6%$180.04+16.9%-24.1%$23.44B$9.68B9.997,605Analyst ForecastAnalyst RevisionINCYIncyte4.3934 of 5 stars$87.23+0.4%$83.64-4.1%+31.4%$16.96B$4.24B21.602,617NBIXNeurocrine Biosciences4.8264 of 5 stars$139.43+1.8%$161.89+16.1%+17.9%$13.59B$2.36B40.541,800IONSIonis Pharmaceuticals3.4196 of 5 stars$69.02-0.2%$75.29+9.1%+84.8%$11.02B$705M0.001,069EXELExelixis4.7675 of 5 stars$40.01-0.2%$44.42+11.0%+50.6%$10.79B$2.17B19.461,147Analyst RevisionEXASExact Sciences4.3244 of 5 stars$57.63+1.6%$68.52+18.9%-14.6%$10.74B$2.76B0.007,000BMRNBioMarin Pharmaceutical4.9339 of 5 stars$55.61+0.3%$92.95+67.1%-25.3%$10.64B$2.85B15.023,040Analyst RevisionMDGLMadrigal Pharmaceuticals4.3949 of 5 stars$442.31-0.2%$495.88+12.1%+102.9%$9.84B$180.13M0.0090Analyst Forecast Related Companies and Tools Related Companies REGN Alternatives ALNY Alternatives BIIB Alternatives INCY Alternatives NBIX Alternatives IONS Alternatives EXEL Alternatives EXAS Alternatives BMRN Alternatives MDGL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:UTHR) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredA Huge Shift Is Underway in AmericaWall Street legend issues chilling new warning: "I've never seen anything as dangerous as this" The man who...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding United Therapeutics Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share United Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
